Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers

Recruiting · NCT06967961 · Interventional (participants receive a specific treatment) · Lead sponsor: Institut Claudius Regaud

View the official record on ClinicalTrials.gov →

Melanoma Prostate cancer

Interventions studied

For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:

What this trial is about

A prospective, proof-of-concept pilot study in patients with metastatic cancers (9 types of cancers are studied) treated at the IUCT-O or possibly in other institutions. Eligible patients will be selected and informed of this study during a medical consultation for their cancer by medical oncologists. Then, with the patient's consent and before the start of anti-cancer treatment (whatever the line), a blood sample will be taken to detect DP-circulating cells by 2 different methods of analysis. Each patient will participate in the study for one day. The methods of analysis will be: flow cytometry for all patients and either Parsotix® or CellSearch® depending on the type of cancer. 450 patients will be enrolled in total.

Who can take part

Age range

18 Years and older

Sex

All (male and female)

Healthy volunteers

No - a diagnosis or condition is required

Phase

Not applicable (e.g. observational or device study)

Study type

Interventional (participants receive a specific treatment)

Inclusion criteria

1\. Patients with one of the following cancer types: urothelial carcinoma, renal carcinoma, prostate adenocarcinoma, upper aerodigestive tract carcinoma, cervival carcinoma, adenocarcinoma of endometrium, cutaneous melanoma, soft tissue sarcoma, seminomatous and nonseminomatous germ cell tumors
2\. Metastatic disease for which the treatment (whatever the line) has not been initiated yet
3\. Age ≥ 18 years
4\. Patient affiliated to a French Social Security scheme
5\. Patient having signed his/her informed consent prior to inclusion in the study and prior to any specific procedure for the study.

Exclusion criteria

1\. Patient with localized disease.
2\. Pregnant or breast-feeding women.
3\. Any psychological, family, geographical or sociological condition that prevents compliance with the medical monitoring and/or procedures set out in the study protocol.
4\. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).

Where it is running

1 location listed.

Oncopole Claudius Regaud, IUCT-O - Toulouse, France

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →